Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 257 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact257 DOIs

Add abstracts to 41 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact41 DOIs

Deposit reference lists for 34 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact34 DOIs

DOIs for this ISSN

Showing the top 5 of 675 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Ovarian vein thrombosis in the nonpregnant woman: an overloo… (10.1177/2040620712450887)	Abstract ORCID	87.79	56
2	Characteristics and survival of BCR/ABL negative chronic mye… (10.1177/2040620715607416)	Abstract ORCID	72.36	27
3	Myeloid sarcoma: current approach and therapeutic options (10.1177/2040620711410774)	ORCID	57.95	207
4	Factor VIII inhibitors in hemophilia A: rationale and latest… (10.1177/2040620712464509)	ORCID	56.91	188
5	Treatment and management of graft- <i>ve… (10.1177/2040620713489842)	ORCID	56.14	175
6	The rise, fall and subsequent triumph of thalidomide: lesson… (10.1177/2040620711413165)	ORCID	56.08	174
7	The evolving role of FLT3 inhibitors in acute myeloid leukem… (10.1177/2040620714532123)	ORCID	54.03	144
8	Inhibition of bromodomain and extra-terminal proteins (BET)… (10.1177/2040620715576662)	ORCID	54.03	144
9	New and emerging therapies for acute and chronic graft… (10.1177/2040620717741860)	ORCID	51.13	110
10	Management of imatinib-resistant patients with chronic myelo… (10.1177/2040620712468289)	ORCID	50.84	107
11	Belinostat in patients with refractory or relapsed periphera… (10.1177/2040620715592567)	ORCID	50.43	103
12	Safety and efficacy of brentuximab vedotin in patients with… (10.1177/2040620712443076)	ORCID	49.89	98
13	Comprehensive review of JAK inhibitors in myeloproliferative… (10.1177/2040620712461047)	ORCID	48.61	87
14	CD19-redirected chimeric antigen receptor-modified T cells:… (10.1177/2040620715588916)	ORCID	48.61	87
15	Genetic predispositions to childhood leukemia (10.1177/2040620713498161)	ORCID	48.36	85
16	Optimal use of thrombopoietin receptor agonists in immune th… (10.1177/2040620719841735)	ORCID	48.36	85
17	<i>JAK2</i> allele burden in the myelopr… (10.1177/2040620710394474)	ORCID	48.24	84
18	The NOTCH signaling pathway: role in the pathogenesis of T-c… (10.1177/2040620712471368)	ORCID	47.02	75
19	Hematopoietic stem-cell transplantation for sickle cell dise… (10.1177/2040620713483063)	ORCID	45.81	67
20	Monitoring minimal residual disease in acute myeloid leukaem… (10.1177/2040620715614529)	ORCID	45.81	67
21	Elotuzumab: the first approved monoclonal antibody for multi… (10.1177/2040620716652862)	ORCID	45.32	64
22	Bruton’s tyrosine kinase inhibitors and their clinical poten… (10.1177/2040620714539906)	ORCID	44.81	61
23	Midostaurin: a novel therapeutic agent for patients with FLT… (10.1177/2040620717721459)	ORCID	44.63	60
24	Azacitidine in the management of patients with myelodysplast… (10.1177/2040620712464882)	ORCID	44.27	58
25	Extracorporeal photopheresis in the treatment of graft-… (10.1177/2040620713490316)	ORCID	44.27	58
26	Invasive fungal infections in acute leukemia (10.1177/2040620711410098)	ORCID	44.09	57
27	Daratumumab and its potential in the treatment of multiple m… (10.1177/2040620715572295)	ORCID	43.70	55
28	Management of thrombosis in paroxysmal nocturnal hemoglobinu… (10.1177/2040620716681748)	ORCID	43.51	54
29	Mogamulizumab for the treatment of cutaneous T-cell lymphoma… (10.1177/2040620716636541)	ORCID	43.31	53
30	The role of blinatumomab in patients with relapsed/refractor… (10.1177/2040620716640422)	ORCID	43.31	53
31	Update on the role of lenalidomide in patients with multiple… (10.1177/2040620718775629)	ORCID	43.31	53
32	The role of enasidenib in the treatment of mutant IDH2 acute… (10.1177/2040620718777467)	ORCID	43.31	53
33	Recognizing familial myeloid leukemia in adults (10.1177/2040620713487399)	ORCID	43.11	52
34	Current and emerging factor VIII replacement products for he… (10.1177/2040620717721458)	ORCID	43.11	52
35	Novel therapies and current clinical progress in hemophilia… (10.1177/2040620717746312)	ORCID	43.11	52
36	Inherited predisposition to myeloproliferative neoplasms (10.1177/2040620713489144)	ORCID	42.69	50
37	Epigenetic regulators as promising therapeutic targets in ac… (10.1177/2040620715577614)	ORCID	42.69	50
38	Recent developments in management of older patients with acu… (10.1177/2040620711434319)	Abstract ORCID	42.25	6
39	Eltrombopag, a thrombopoietin- receptor agonist in the treat… (10.1177/2040620712442525)	ORCID	42.25	48
40	Targeting the leukemia–stroma interaction in acute myeloid l… (10.1177/2040620715619307)	ORCID	42.25	48
41	Review of siltuximab in the treatment of multicentric Castle… (10.1177/2040620716653745)	ORCID	42.25	48
42	The evolution of clonality testing in the diagnosis and moni… (10.1177/2040620713519729)	ORCID	41.80	46
43	Differentiating malignant hypertension-induced thrombotic mi… (10.1177/2040620715571076)	ORCID	41.80	46
44	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inh… (10.1177/2040620712459746)	ORCID	41.57	45
45	Diagnosis and management of primary autoimmune neutropenia i… (10.1177/2040620714556642)	ORCID	41.57	45
46	Splanchnic vein thrombosis in myeloproliferative neoplasms:… (10.1177/2040620716680333)	ORCID	41.57	45
47	Novel agents for the treatment of childhood acute leukemia (10.1177/2040620714565963)	ORCID	41.33	44
48	Bortezomib for the treatment of mantle cell lymphoma: an upd… (10.1177/2040620716648566)	ORCID	40.58	41
49	Serum free light-chain assay for the detection and monitorin… (10.1177/2040620712466863)	ORCID	40.32	40
50	The potential of venetoclax (ABT-199) in chronic lymphocytic… (10.1177/2040620716655350)	ORCID	40.32	40